Garret M. Hampton

11.8k citations

93 papers · 9.1k indexed · 4 hit papers · h-index 45

Cancer Research top 0.5%
- Cancer Genomics and Diagnostics 18
Oncology top 1%
Molecular Biology top 1%
- Gene expression and cancer classification 13
- RNA modifications and cancer 13
- PI3K/AKT/mTOR signaling in cancer 9
- Genomics and Chromatin Dynamics 7
- Epigenetics and DNA Methylation 7
- Molecular Biology Techniques and Applications 7
Reproductive Medicine top 1%
Pathology and Forensic Medicine top 1%
- Genetic factors in colorectal cancer 9

Co-authors: Henry F. Frierson Lisa M. Sapinoso S Kern Christopher A. Moskaluk Peter G. Schultz Andrew I. Su Dan Theodorescu Steven M. Powell
Cited by: Cancer Research Oncology Molecular Biology
Journals: Proceedings of the National Academy of Sciences (8 papers)Nature Communications (1 paper)Nature Genetics (2 papers)
Partner nations: United States United Kingdom China

In The Last Decade

Garret M. Hampton

93 papers receiving 8.8k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2002 Proceedings of the National Academy of Sciences
2002 Molecular Cell
2001 Proceedings of the National Academy of Sciences
2001 PubMed

Peers

Countries citing papers authored by Garret M. Hampton

Since Specialization

Citations

This map shows the geographic impact of Garret M. Hampton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Garret M. Hampton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Garret M. Hampton more than expected).

Fields of papers citing papers by Garret M. Hampton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Garret M. Hampton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Garret M. Hampton. The network helps show where Garret M. Hampton may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Garret M. Hampton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Garret M. Hampton Line = papers co-authored together Garret M. Hampton links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110β Cancer Research ·Yoshito Nakanishi,Kimberly Walter,Jill M. Spoerke,Carol O’Brien,Ling Huw,Garret M. Hampton,Mark R. Lackner	2016	55
2	Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC Annals of Oncology ·Marcin Kowanetz,Wei Zou,David S. Shames,C. Cummings,Naiyer A. Rizvi,Alexander I. Spira,Garrett M. Frampton,Vincent Lévêque,Shannon L. Flynn,Simonetta Mocci,G. Shankar,Roel Funke,M. Ballinger,Daniel Waterkamp,A. Sandler,Garret M. Hampton,Lukas C. Amler,Priti S. Hegde,Matthew D. Hellmann	2016	34
3	High-Throughput Detection of Clinically Relevant Mutations in Archived Tumor Samples by Multiplexed PCR and Next-Generation Sequencing Clinical Cancer Research ·Richard Bourgon,Shan Lu,Yibing Yan,Mark R. Lackner,Weiru Wang,Victor Weigman,David Wang,Yinghui Guan,Lisa Ryner,Hartmut Koeppen,Rajesh Patel,Garret M. Hampton,Lukas C. Amler,Yulei Wang	2014	52
4	Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples Breast Cancer Research and Treatment ·Timothy R. Wilson,Yuanyuan Xiao,Jill M. Spoerke,Jane Fridlyand,Hartmut Koeppen,Eloisa Fuentes,Ling Huw,Ilma Abbas,Arjan Gower,Erica Schleifman,Rupal Desai,Ling Fu,Teiko Sumiyoshi,Joyce O’Shaughnessy,Garret M. Hampton,Mark R. Lackner	2014	21
5	HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors Molecular Cancer Therapeutics ·Elicia Penuel,Congfen Li,Vaishali Parab,Luciana Burton,Kyra J. Cowan,Mark Merchant,Robert L. Yauch,Premal H. Patel,Amy Peterson,Garret M. Hampton,Mark R. Lackner,Priti S. Hegde	2013	20
6	Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib Clinical Cancer Research ·Elizabeth A. Punnoose,Siminder Atwal,Weiqun Liu,Rajiv Raja,Bernard M. Fine,Brett Hughes,Rodney J. Hicks,Garret M. Hampton,Lukas C. Amler,Andrea Pirzkall,Mark R. Lackner	2012	341
7	DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer Clinical Cancer Research ·Walter Kim,Thomas Holcomb,Tom Januario,Pan Du,Marie Evangelista,Nithya Kartha,Leonardo Iniguez,Robert Soriano,Ling Huw,Howard M. Stern,Zora Modrušan,Somasekar Seshagiri,Garret M. Hampton,Lukas C. Amler,Richard Bourgon,Robert L. Yauch,David S. Shames	2012	66
8	Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models Clinical Cancer Research ·Jill M. Spoerke,Carol O’Brien,Ling Huw,Hartmut Koeppen,Jane Fridlyand,Rainer K. Brachmann,Peter M. Haverty,Ajay Pandita,Sankar Mohan,Deepak Sampath,Lori S. Friedman,Leanne Ross,Garret M. Hampton,Lukas C. Amler,David S. Shames,Mark R. Lackner	2012	149
9	ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors Molecular Cancer Therapeutics ·Georgia Hatzivassiliou,Bonnie Liu,Carol O’Brien,Jill M. Spoerke,Klaus P. Hoeflich,Peter M. Haverty,Robert Soriano,William F. Forrest,Sherry Heldens,Huifen Chen,Karen Toy,Connie Ha,Wei Zhou,Kyung Song,Lori S. Friedman,Lukas C. Amler,Garret M. Hampton,John G. Moffat,Marcia Belvin,Mark R. Lackner	2012	155
10	Prostate cancer – a biomarker perspective Frontiers in Endocrinology ·Yanqiu Liu,Priti S. Hegde,Feng‐Min Zhang,Garret M. Hampton,Shidong Jia	2012	20
11	Profiling Bladder Cancer Organ Site-Specific Metastasis Identifies LAMC2 as a Novel Biomarker of Hematogenous Dissemination American Journal Of Pathology ·Steven C. Smith,Brian Nicholson,Matthew D. Nitz,Henry F. Frierson,Mark E. Smolkin,Garret M. Hampton,Wael El‐Rifai,Dan Theodorescu	2009	29
12	An Integrated Clinical-Genomics Approach Identifies a Candidate Multi-Analyte Blood Test for Serous Ovarian Carcinoma Clinical Cancer Research ·Ivo Meinhold‐Heerlein,Dirk Bauerschlag,Yingyao Zhou,Lisa M. Sapinoso,Keith A. Ching,Henry F. Frierson,Karen Bräutigam,Jalid Sehouli,Elmar Stickeler,Dominique Könsgen,Felix Hilpert,Constantin S. von Kaisenberg,Jacobus Pfisterer,Thomas Bauknecht,W. Jonat,Norbert Arnold,Garret M. Hampton	2007	41
13	Overexpression of CEBPβ correlates with decreased TFF1 in gastric cancer Oncogene ·Narendra V. Sankpal,Christopher A. Moskaluk,Garret M. Hampton,Steven M. Powell	2005	23
14	RNAi and HTS: exploring cancer by systematic loss-of-function Oncogene ·Aarron Willingham,Quinn L. Deveraux,Garret M. Hampton,Pedro Aza‐Blanc	2004	48
15	Overexpression of the 32‐kilodalton dopamine and cyclic adenosine 3′,5′‐monophosphate‐regulated phosphoprotein in common adenocarcinomas Cancer ·Andy Beckler,Christopher A. Moskaluk,Alexander Zaika,Garret M. Hampton,Steven M. Powell,Henry F. Frierson,Wa'el El‐Rifai	2003	52
16	Activation and Suppression of the TRAIL Death-Receptor Pathway in Chemotherapy Sensitive and Resistant Follicular Lymphoma Cells Cancer Biology & Therapy ·Klaus W. Wagner,Fred King,Ken Nomoto,Deborah Knee,Garret M. Hampton,Marc Nasoff,Quinn L. Deveraux	2003	8
17	An integrated view of aromatase and its inhibition The Journal of Steroid Biochemistry and Molecular Biology ·William R. Miller,Thomas Anderson,Dean B. Evans,Andreas Krause,Garret M. Hampton,J. Michael Dixon	2003	34
18	Microsatellite instability in cervical carcinoma European Journal of Obstetrics & Gynecology and Reproductive Biology ·Tony K.H. Chung,Tsz-Ming Ip,Garret M. Hampton,Vivian W. Wang,Tak Hong Cheung,Y.F. Wong	2001	4
19	Arrays of Arrays for High-Throughput Gene Expression Profiling Genome Research ·Patrick P. Zarrinkar,James Mainquist,Matthew T. Zamora,David L. Stern,John Welsh,Lisa M. Sapinoso,Garret M. Hampton,David J. Lockhart	2001	30
20	Identification and Characterization of Novel Genes Located at the t(1;15)(p36.2;q24) Translocation Breakpoint in the Neuroblastoma Cell Line NGP Genomics ·Lukas C. Amler,Anja Bauer,Raffaella Corvi,Susanne Dihlmann,Christian Praml,Webster K. Cavenee,Manfred Schwab,Garret M. Hampton	2000	18

About Garret M. Hampton

Garret M. Hampton is a scholar working on Cancer Research, Oncology and Molecular Biology, having authored 93 papers that have together received 9.1k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (18 papers), Gene expression and cancer classification (13 papers), RNA modifications and cancer (13 papers), PI3K/AKT/mTOR signaling in cancer (9 papers), Genetic factors in colorectal cancer (9 papers), Genomics and Chromatin Dynamics (7 papers), Epigenetics and DNA Methylation (7 papers) and Molecular Biology Techniques and Applications (7 papers). The work is most often cited by research in Cancer Research (1.9k citations), Oncology (2.6k citations) and Molecular Biology (5.6k citations). Garret M. Hampton has collaborated with scholars based in United States, United Kingdom and China. Frequent co-authors include Henry F. Frierson, Lisa M. Sapinoso, S Kern, Christopher A. Moskaluk, Peter G. Schultz, Andrew I. Su, Dan Theodorescu, Steven M. Powell, Mary T. Galgano and John Welsh. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nature Communications and Nature Genetics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact